MedTrace Logo

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

NCT02049905 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 433

Last updated 2024-06-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.

Conditions

  • Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

Interventions

DRUG

Aldoxorubicin

DRUG

Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)

Sponsors & Collaborators

  • ImmunityBio, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • United States
  • Australia
  • Canada
  • Chile
  • Denmark
  • France
  • Hungary
  • Israel
  • Italy
  • Netherlands
  • Poland
  • Russia
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02049905 on ClinicalTrials.gov